High fragmentation in platelet concentrates impacts the activation, procoagulant, and aggregatory capacity of platelets.


Journal

Platelets
ISSN: 1369-1635
Titre abrégé: Platelets
Pays: England
ID NLM: 9208117

Informations de publication

Date de publication:
Dec 2023
Historique:
entrez: 12 1 2023
pubmed: 13 1 2023
medline: 14 1 2023
Statut: ppublish

Résumé

Platelets are transfused to patients to prevent bleeding. Since both preparation and storage can impact the hemostatic functions of platelets, we studied platelet concentrates (PCs) with different initial composition in regard to platelet fragmentation and its impact on storage-induced changes in activation potential. Ten whole blood derived PCs were assessed over 7 storage days. Using flow cytometry, platelet (CD41+) subpopulations were characterized for activation potential using activation markers (PAC-1, P-selectin, and LAMP-1), phosphatidylserine (Annexin V), and mitochondrial integrity (DiIC What is the context?● Platelets are necessary to prevent and stop bleeding.● Conditions associated with a low platelet count in the circulation, such as during chemotherapy treatment for hematologic cancer, can result in life-threatening bleeding. To prevent this, platelets from blood donors are transfused to these patients.● The collection and preparation of platelet concentrates and subsequent storage before transfusion can affect the ability of the platelets to prevent bleeding.● In this study, we investigated platelet concentrates prepared from whole blood and how their activation capacity was affected by the preparation and storage period.What is new?● We found that the platelet concentrates contained mainly low activated platelets of normal size, but also smaller platelets and platelet fragments.● Unlike normal-sized platelets, small platelets and fragments exhibited hallmarks that are characteristic of pre-activation.● Some platelet concentrates contained a relatively high proportion of small platelets and fragments already directly following preparation.● Investigating several platelet activation markers, we found that platelet concentrates containing a high proportion of small platelets and platelet fragments showed lower activation capacity throughout the storage period.

Autres résumés

Type: plain-language-summary (eng)
What is the context?● Platelets are necessary to prevent and stop bleeding.● Conditions associated with a low platelet count in the circulation, such as during chemotherapy treatment for hematologic cancer, can result in life-threatening bleeding. To prevent this, platelets from blood donors are transfused to these patients.● The collection and preparation of platelet concentrates and subsequent storage before transfusion can affect the ability of the platelets to prevent bleeding.● In this study, we investigated platelet concentrates prepared from whole blood and how their activation capacity was affected by the preparation and storage period.What is new?● We found that the platelet concentrates contained mainly low activated platelets of normal size, but also smaller platelets and platelet fragments.● Unlike normal-sized platelets, small platelets and fragments exhibited hallmarks that are characteristic of pre-activation.● Some platelet concentrates contained a relatively high proportion of small platelets and fragments already directly following preparation.● Investigating several platelet activation markers, we found that platelet concentrates containing a high proportion of small platelets and platelet fragments showed lower activation capacity throughout the storage period.

Identifiants

pubmed: 36632714
doi: 10.1080/09537104.2022.2159018
doi:

Substances chimiques

Annexin A5 0
P-Selectin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2159018

Auteurs

Nahreen Tynngård (N)

Department of Clinical Chemistry and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Research and Development Unit in Region Östergötland and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Aseel Alshamari (A)

Department of Clinical Immunology and Transfusion medicine, Faculty of Medicine and Health, Örebro University, Sweden.
Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Per Sandgren (P)

Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.

Dermot Kenny (D)

Clinical Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.

Ana Maria Vasilache (AM)

Department of Clinical Immunology and Transfusion Medicine, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Mohammad R Abedi (MR)

Department of Clinical Immunology and Transfusion medicine, Faculty of Medicine and Health, Örebro University, Sweden.

Sofia Ramström (S)

Department of Clinical Chemistry and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH